RxDoctor Payments Data

John Niles, MD

Nephrology · Boston, MANPI 1316912033

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (31.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by AstraZeneca at 45.9% of the total.

$12,809in general payments, 2019–2025

Across 46 payments — averaging $278.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • F. Hoffmann-la Roche AG$4K
  • Amgen$2K
  • Apellis Pharmaceuticals, Inc.$241
  • Genentech, Inc.$107
  • Travere Therapeutics, Inc.$20
$585,409in research payments, 2019–2025

Across 13 payments — averaging $45,031 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$328K
  • AstraZeneca$252K
  • F. Hoffmann-la Roche AG$5K

What the payments were for

  • Consulting fees$3,45627%
  • Speaking & faculty fees$4,06432%
  • Travel & lodging$3,31126%
  • Food & beverage$1,85114%
  • Education$1271%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,809 in reported general payments places this provider in the 80th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$1,217,702
Medicare patients
316
Services billed
33,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab11$561,417
TavneosAvacopan18$283,292
NucalaMepolizumab11$121,051
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$83,076
BivigamImmun Glob G(Igg)/Gly/Iga Ov5011$61,481
Cyclophosphamide12$2,237
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$567
Prednisone39$528
Fluocinonide11$412
Omeprazole19$327
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide13$305
Carvedilol19$291
Amlodipine Besylate23$269
Furosemide21$245
Losartan Potassium24$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$5,884$561,41711 claims
AmgenTavneos$2,494$283,29218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →